West Nile virus (WNV)-immune spleen cells produced an inducer of macrophage procoagulant activity (MPCA) on restimulation with WNV in vitro. This response was specific for WNV and depended on the presence ofThy 1 +, L3T4 + and also Ia + cells but not Lyt 2 ÷ cells. It could be induced by culture with large amounts of non-infectious, u.v.-irradiated virus or with high doses of infectious virus. Inoculation of mice with low titres of infectious, but not with u.v.-irradiated, virus primed for this in vitro response. The time of maximum production of procoagulant-inducing factor was also the period of greatest [3H]thymidine uptake and release of interleukin-2 (IL-2)-like activity. In bulk cultures, MPCA-inducing factor was more readily quantified than IL-2. T cells of the helper/delayed-type hypersensitivity class are thus stimulated by WNV and this aspect of cell-mediated immunity can be readily assayed in vitro.
INTRODUCTION
The role of cell-mediated immunity (CMI) in flavivirus infection is not clearly understood, although antibody responses have been studied in considerable detail for many years. Cytotoxic T lymphocyte activity has, in particular, been difficult to demonstrate (for review, see Doherty, 1984) . Even so, there have been occasional reports of the ability of some flaviviruses to induce cytotoxic T cells (Gajdosova et al., 1981) , delayed-type hypersensitivity (DTH) (Pang et al., : 1982) , macrophage migration inhibition factor (Kelkar & Banerjee, 1978) and antibodydependent cell-mediated cytotoxicity (Kurane et al., 1984) . Both immune T cells (Jacoby et al., 1980) and specific antibody (Chaturvedi et al., 1978) have been shown to protect on adoptive transfer, although there is also evidence that the host response may have deleterious consequences in some situations (Camenga & Nathanson, 1975; Semenov et aL, t975) . The best known example of immunopathology in a flavivirus infection is the dengue haemorrhagic shock syndrome, which could result from antibody-mediated enhancement of virus replication in macrophage during secondary infection (Halstead, 1982) . It is possible that the T cell response also contributes to the development of disease, either directly or via regulatory effects on antibody production. Such analyses have been hindered by the lack of appropriate in vitro assays.
The aim of the present paper is to describe the evaluation of a simple, in vitro T cell assay using West Nile virus (WNV). It depends on the capacity of WNV-immune T cells to induce macrophage procoagulant activity (MPCA). This study was carried out because the MPCA assay has been shown, in other systems, to be a more sensitive measure of DTH in vivo than either lymphocyte proliferation or the capillary tube test for macrophage migration inhibition (Geczy & Meyer, 1982; Geczy et al., 1983) .
METHODS
Mice. Inbred, CBA/H and outbred WEHI mice were bred at the John Curtin School of Medical Research. Viruses. WNV (Sarafend strain) and Semliki Forest virus (SFVI were kindly provided as suckling brain 0000-6654 © 1986 SGM homogenates by Dr I. Marshall, Department of Microbiology, John Curtin School of Medical Research. These were passaged a further once or twice by intracerebral injection of newborn CBA/H mice. Uninfected 5-day-old CBA/H brain was prepared as control antigen. Virus stocks consisted of a 10~o brain homogenate, sonicated in gelatin saline followed by centrifugation at 1500 g for 20 min at 4 °C. Aliquots of suPernatant were stored at -70 °C. Sterility was checked by incubation on blood agar plates for 7 days at 37 °C. Virus for u.v. irradiation was diluted 1/12 and 0.5 ml in a 19.6 cm 2 plastic Petri dish (Sterilin) was irradiated with 6 J/mZ/s for 9 min. This preparation did not kill newborn mice on intracerebral inoculation. Control virus was not irradiated but otherwise was treated similarly.
Virus titration. Assays for p.f.u, were carried out on Vero cells grown in 6-well Linbro plates (9.6 cm-') in RPMI 1640 medium containing 109/o foetal calf serum (FCS), 100 units/ml penicillin, 100 p.g/ml streptomycin and 100 ~tg/ml neomycin (PSN). Confluent monolayers were washed three times and 0.2 ml of serial twofold dilutions of virus added to duplicate wells. After incubation at 37 °C for 1 h with gentle rocking, the inoculum was removed and 2 ml medium containing 29/0 FCS, PSN and 0.75% agar were added. Cultures were incubated at 37 °C in 5~ CO, for 3 days for SFV (101 l.t p.f.u./ml) and 5 days for WNV (109.5 p.f.u./ml). Monolayers were stained with 1 methylene blue containing 10~ formalin and plaques were counted.
Priming. Adult CBA/H mice were inoculated by the intraperitoneal route with 0-2 ml WNV to give 107.2 p.f.u./mouse unless stated otherwise.
Spleen cell preparations. Spleens were collected aseptically, minced finely, pushed through a stainless steel grid and passed through gauze to remove clumps. The single cell suspension, prepared in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS and PSN, was washed once at 400g for l0 min at 4 °C. Ceils were layered on Ficoll Hypaque and centrifuged at 2000 g for 20 min at 22 °C resulting in less than 2~ red blood cell contamination. Following one wash, viable cell counts were determined, based on exclusion of trypan blue dye.
Restimulation in vitro. Spleen cells at 1.7 x l0 b cells/ml in DMEM with 10~ FCS, PSN, 10 -a M-2-mercaptoethanol, L-glutamine and non-essential amino acids (CSL, Melbourne, Victoria, Australia) were dispensed in flat-bottom 96-well N unc trays at 225 !-d/well. After addition of 25 ~1 of antigen/well, cultures were incubated at 37 °C in 5% CO., for 3 days unless stated otherwise. Supernatants were stored at -70 °C until titration.
Procoagulant assay. All solutions used in the preparation and assay of samples to be tested for MPCA had been passed through Zetapor filters (American Machine & Foundary Co., Chatswood, Australia) to remove endotoxin. PU5-1.8 cells, a continuous macrophage line derived from BALB/c mice, were incubated at 200 btl of l06 cells/ml with 100 ~tl of test sample in minisorb tubes (Nunc) for 15 to 20 h at 37 °C in 5 ~ CO,. Then cells were washed once in Hanks" balanced salt solution and twice in phosphate-buffered saline (PBS). Cells were resuspended in 220 ~tl PBS and 100 ~tl added to 100 ~tl of platelet-deficient mouse plasma. Plasma was recalcified by addition of 100 ~tl 0.3 ra-CaCl_, immediately before measuring clotting time in a fibrinometer (BBL Fibro Systems, Becton, Dickinson & Co., Sunnyvale, Ca., U.S.A.) as described by Geczy et al. (1983) . The percent reduction in clotting time was calculated from [(clotting time of control -clotting time of test)/clotting time of control] × 100.
Proli[eration assay. Spleen cells (106/ml) were dispensed into 96-well fiat-bottom plates (Nunc) at 200 ~L1/well and 25 ~tl antigen added. After 24 h incubation, 0.2 ~tCi/well thymidine was added and cultures incubated for 24 h. Samples were harvested onto filter papers using a multiple sample harvester (Skatron, Norway) and transferred to 5 ml of scintillation fluid (xylene/PPO) and counted in a Tri-carb liquid scintillation spectrometer (Packard).
Interleukin-2 assay. The ability of samples to support proliferation of concanavalin A (Con A)-stimulated spleen cells was measured by [3H]thymidine uptake as described by Lafferty et al. (1980) . Fifty ~tl of sample was added to 50 ~al Con A blasts. Control wells consisted of cells and medium or cells and a standard supernatant which contained interleukin-2 (IL-2).
Antibody treatment. Monoclonal antibodies were: anti-Thy 1.2 (clone F7D5, Olac Ltd., Bicester, Oxon, U.K. ; 1/103); anti-Lyt 2.1 (MLEUKO3, AMD, New South Wales, Australia; 1/103); anti-L3T4 (GK1.5 cell line, Dialynas et al., 1983; 1/20) and anti-IA k (line 11-52.1, Oi et al., 1978; 1/20) . The optimum concentrations were determined by complement-dependent lysis of normal thymocytes or spleen cells. Antibody alone was not toxic as determined by exclusion of trypan blue dye. Cell depletion using low toxicity rabbit complement has been described previously (Allan & Doherty, 1985) .
RESULTS
Spleen cells from mice infected with WNV 1 to 2 months previously were restimulated with WNV or control antigen in vitro. High levels of proliferation were observed in response to WNV from day 3, with a reduced response from day 4 (Fig. 1) . It was also found, as shown in Fig. 2 , that WNV-restimulated cultures contained procoagulant-inducing factor on days 2 to 5 after stimulation, with maximum activity on days 3 to 4. The production of the MPCA-inducing factor involved immune recognition of WNV, since cells from mice inoculated with normal brain homogenate did not produce MPCA-inducing factor on in vitro stimulation with WNV (Fig. 3) . Furthermore, there was no response to normal brain antigen in cultures from WNVprimed mice (Fig. 3) . Specificity for WNV was also shown by the consistent failure (in each of five experiments) of the alphavirus, SFV, to stimulate MPCA-inducing activity from WNVprimed cells (Fig. 3) . The magnitude of the response was largely independent of the dose of W NV used to prime the mice (Fig. 4) . Infection with 107.2 p.f.u./mouse gave as high a level of activity as 1012 
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in Fig. 2 , 3 and 4 and Table 1 which were performed over a period of 12 months. In addition, it should be noted that each of these results is representative of at least two independent experiments. Immune spleen cells were depleted of Thy 1 +, L3T4 +, Lyt 2 + or la + cells by treatment with monoclonal antibody and complement prior to restimulation in vitro. Removal of Thy 1 + cells completely abrogated the capacity to induce MPCA (groups B and F, Table 3 ). Elimination of the L3T4 + (groups C and G, Table 3 ) and Ia ÷ (groups H and L, Table 3 ), but not the Lyt 2 + (groups D and K, Table 3), cell populations was also highly suppressive. The addition of normal spleen cells to cultures depleted of Ia + cells (groups L to N, Table 3 ) did not substantially restore production of MPCA-inducing factor, suggesting that at least some of the Ia + cells that are required are immunocytes, probably T cells.
Lymphocytes of the Thy 1 +, L3T4 + phenotype also produce relatively high concentrations of IL-2, which can be measured by the capacity of culture supernatants to support Con A blast proliferation. The ability of supernatants from cultures of WNV-primed spleen to support Con A blast proliferation was maximum at 3 days after addition of WNV. At this time there was an I l-fold greater uptake of [3H]thymidine in Con A blast populations containing supernatant from WNV, in comparison to that from normal brain homogenate-stimulated cultures (Fig. 5) .
DISCUSSION
An #~ vitro test for the measurement of helper-DTH T cell activity has been needed for a long time. Assays for T helper activity through collaboration with B cells, and of DTH by measuring the extent of footpad swelling, are cumbersome and, in the latter case, relatively insensitive. The MPCA, in contrast, is simple, quantitative and can be used for species as diverse as man (Geczy & Meyer, 1982) and mouse. Although production of this factor is dependent on Ia homology between T cell and antigen-presenting cell (Levy & Edgington, 1982; Schiltknecht et al., 1984) , there are sufficient Ia + stimulator cells in, for example, human peripheral blood for the reaction to proceed (Geczy & Meyer, 1982) . Production of IL-2, which has been used more recently as a marker for activation of class II-restricted T cells, was apparently present following restimulation with WNV. However, the low levels produced were difficult to quantify accurately in situations where MPCA was easily detected. The MPCA assay has proved extremely useful in studies of the pathogenesis of experimental allergic encephalitis in rats and guinea-pigs (Bowern et al., 1984; Geczy et al., 1984) but it has not been used extensively to analyse either immunity or immunopathology in virus-induced disease. Apart from the results presented here, the characteristics of the MPCA assay system have received some attention for mouse hepatitis virus type 3 (Levy et al., 1981) and for influenza A viruses (Schiltknecht et al., 1984) . One difference from our findings is that in the influenza A model, Lyt 2 + T cells were found to be capable of inducing low levels of MPCAinducing factor. However, induction of Lyt 2 + cytotoxic T cell activity has proved much easier for paramyxoviruses than for flaviviruses (Doherty, 1984) , which may be a consequence of the fact that paramyxoviruses bud from the cell surface whereas flaviviruses bud internally. However, this line of argument is weakened by recent gene transfection experiments which indicate that most influenza-immune cytotoxic T cells are directed at an antigenic entity associated in some way with the virus ribonucleoprotein gene which codes for a component that is internal to the virion (Townsend et al., 1984) . The lack of virus budding from the cell surface, or expression of viral proteins at the plasma membrane, should not affect stimulation of L3T4 ÷ T cells, since such lymphocytes are generally considered to respond to antigen which has been processed by macrophages or dendritic cells prior to presentation in an immunogenic form (Van Voorhis et al., 1983; Unanue et al., 1984) .
The identity of the MPCA-inducing factor is not yet known. According to Dr C. Geczy (personal communication) it differs from IL-2, macrophage-activating factor, macrophage migration inhibition factor and gamma interferon. It is possible that the MPCA-inducing factor is produced by L3T4 ÷ cells or by Ia ÷ T cells, or as a result of the interaction between separate sets of L3T4 ÷ and Ia ÷ cells. This should be clarified when cloned T cell lines of appropriate function and specificity are developed. Such studies are also required to determine whether the same cells can produce IL-2 and MPCA-inducing factor and whether they do so in a coordinate fashion. Since the role of MPCA-inducing factor, unlike IL-2, appears to be to regulate the response of macrophages, this assay has the potential of addressing the effect of a specific immune response on the activity of these cells.
Our principal interest in the MPCA assay is to use it to assess specificity patterns for flavivirus-immune helper-DTH T cells, and to examine the effect of different degrees of such cross-priming on pathogenesis. The findings to date (unpublished data) indicate that there is extensive cross-reactivity for WNV-immune and Kunjin virus-immune T cells, but that this is less apparent for Murray Valley encephalitis and for dengue viruses. It will be necessary to test cloned T cells in this way. An additional interest lies with the possibility that MPCA production in lesions may have immunopathological consequences. (Received 17 April 1985) 
